2022
Hay, J., Tarafdar, A., Holroyd, A. K., Moka, H. A., Dunn, K. M., Alshayeb, A., . . . Michie, A. M. (2022). PKC beta Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling. CANCERS, 14(23). doi:10.3390/cancers14236006DOI: 10.3390/cancers14236006
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features (Journal article)
Robbe, P., Ridout, K. E., Vavoulis, D. V., Dreau, H., Kinnersley, B., Denny, N., . . . Schuh, A. (2022). Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. NATURE GENETICS, 54(11), 1675-+. doi:10.1038/s41588-022-01211-yDOI: 10.1038/s41588-022-01211-y
Zijlstra, J. M., Follows, G., Casasnovas, R. -O., Vermaat, J. S. P., Kalakonda, N., Choquet, S., . . . Maerevoet, M. (2022). The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. CANCERS, 14(3). doi:10.3390/cancers14030791DOI: 10.3390/cancers14030791
Safety and efficacy of durvalumab with R-CHOP or R-2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial (Journal article)
Nowakowski, G. S., Willenbacher, W., Greil, R., Larsen, T. S., Patel, K., Jaeger, U., . . . Munoz, J. (2022). Safety and efficacy of durvalumab with R-CHOP or R-2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. INTERNATIONAL JOURNAL OF HEMATOLOGY, 115(2), 222-232. doi:10.1007/s12185-021-03241-4DOI: 10.1007/s12185-021-03241-4
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes (Journal article)
Casasnovas, R. -O., Follows, G., Zijlstra, J. M., Vermaat, J. S. P., Kalakonda, N., Choquet, S., . . . Goy, A. (2022). Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 22(1), 24-33. doi:10.1016/j.clml.2021.07.017DOI: 10.1016/j.clml.2021.07.017
Hounsome, L., Eyre, T. A., Ireland, R., Hodson, A., Walewska, R., Ardeshna, K., . . . Fields, P. A. (2022). Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England. BRITISH JOURNAL OF CANCER, 126(1), 134-143. doi:10.1038/s41416-021-01525-4DOI: 10.1038/s41416-021-01525-4
2021
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study (Journal article)
Schuster, M., Zijlstra, J., Casasnovas, R. -O., Vermaat, J. S. P., Kalakonda, N., Goy, A., . . . Maerevoet, M. (2021). Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. Clinical Lymphoma Myeloma and Leukemia. doi:10.1016/j.clml.2021.12.016DOI: 10.1016/j.clml.2021.12.016
Khan, U. T., Kelly, M., Dodd, J., Fergiani, S., Hammer, B., Smith, J., . . . Menon, G. (2021). Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study. JOURNAL OF CLINICAL PATHOLOGY, 74(12), 816-818. doi:10.1136/jclinpath-2020-207121DOI: 10.1136/jclinpath-2020-207121
Linley, A. J., Karydis, L. I., Mondru, A. K., D'Avola, A., Al Shmrany, H., Cicconi, S., . . . Slupsky, J. R. (2021). Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. CLINICAL CANCER RESEARCH, 27(20), 5647-5659. doi:10.1158/1078-0432.CCR-21-0161DOI: 10.1158/1078-0432.CCR-21-0161
Duell, J., Maddocks, K. J., Gonzalez-Barca, E., Jurczak, W., Liberati, A. M., de Vos, S., . . . Salles, G. (2021). Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. In HAEMATOLOGICA Vol. 106 (pp. 2417-2426). doi:10.3324/haematol.2020.275958DOI: 10.3324/haematol.2020.275958
Maerevoet, M., Zijlstra, J. M., Follows, G., Casasnovas, R. -O., Vermaat, J. S. P., Kalakonda, N., . . . Canales, M. (2021). Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. JOURNAL OF HEMATOLOGY & ONCOLOGY, 14(1). doi:10.1186/s13045-021-01122-1DOI: 10.1186/s13045-021-01122-1
Shah, J., Shacham, S., Kauffman, M., Daniele, P., Tomaras, D., Tremblay, G., . . . Canales Albendea, M. A. (2021). Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. FUTURE ONCOLOGY, 17(11), 1295-1310. doi:10.2217/fon-2020-0946DOI: 10.2217/fon-2020-0946
Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865DOI: 10.1080/10428194.2021.1876865
2020
Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact Reply (Journal article)
Kalakonda, N., Kauffman, M., & Shah, J. (2020). Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact Reply. LANCET HAEMATOLOGY, 7(10), E707-E708. Retrieved from https://www.webofscience.com/
Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial (Journal article)
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J. S. P., . . . Canales, M. A. (2020). Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial. The Lancet Haematology, 7(7), E509-E522. doi:10.1016/S2352-3026(20)30120-4DOI: 10.1016/S2352-3026(20)30120-4
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study (Journal article)
Salles, G., Duell, J., Gonzalez Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., . . . Maddocks, K. (2020). Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet Oncology, 21(7), 978-988. doi:10.1016/S1470-2045(20)30225-4DOI: 10.1016/S1470-2045(20)30225-4
Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805DOI: 10.3324/haematol.2019.230805
2019
Duckworth, A. D., Gherardini, P. F., Sykorova, M., Yasin, F., Nolan, G. P., Slupsky, J. R., & Kalakonda, N. (2019). Multiplexed profiling of RNA and protein expression signatures in individual cells using flow or mass cytometry. Nature Protocols, 14(03), 901-920. doi:10.1038/s41596-018-0120-8DOI: 10.1038/s41596-018-0120-8
Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R-2-CHOP in subjects with previously untreated, high-risk DLBCL. (Conference Paper)
Nowakowski, G. S., Willenbacher, W., Greil, R., Larsen, T. S., Patel, K., Jager, U., . . . Munoz, J. (2019). Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R-2-CHOP in subjects with previously untreated, high-risk DLBCL.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from https://www.webofscience.com/
2018
Anderson, R. A., Remedios, R., Kirkwood, A. A., Patrick, P., Stevens, L., Clifton-Hadley, L., . . . Johnson, P. W. M. (2018). Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. The Lancet. Oncology, 19(10), 1328-1337. doi:10.1016/S1470-2045(18)30500-XDOI: 10.1016/S1470-2045(18)30500-X
Atherton, K., Young, B., Kalakonda, N., & Salmon, P. (2018). Perspectives of patients with haematological cancer on how clinicians meet their information needs: "Managing" information versus "giving" it. PSYCHO-ONCOLOGY, 27(07), 1719-1726. doi:10.1002/pon.4714DOI: 10.1002/pon.4714
Gleeson, M., Peckitt, C., To, Y. M., Edwards, L., Oates, J., Wotherspoon, A., . . . Cunningham, D. (2018). CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. LANCET HAEMATOLOGY, 5(5), E190-E200. doi:10.1016/S2352-3026(18)30039-5DOI: 10.1016/S2352-3026(18)30039-5
2017
Till, K. J., Allen, J. C., Talab, F., Lin, K., Allsup, D., Cawkwell, L., . . . Slupsky, J. R. (2017). Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. SCIENTIFIC REPORTS, 7. doi:10.1038/s41598-017-17021-wDOI: 10.1038/s41598-017-17021-w
Al-Sanabra, O., Duckworth, A. D., Glenn, M. A., Brown, B. R., Angelillo, P., Lee, K., . . . Slupsky, J. R. (2017). Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells. Scientific Reports, 7. doi:10.1038/srep43228DOI: 10.1038/srep43228
Investigating the CLL kinome to understand BCR signaling dynamics and the influence of kinase inhibitors (Conference Paper)
Slupsky, J., Prior, I., MacEwan, D., Wilson, L., Linley, A., & Kalakonda, N. (2017). Investigating the CLL kinome to understand BCR signaling dynamics and the influence of kinase inhibitors. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 3-4). Retrieved from https://www.webofscience.com/
2016
Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain (Journal article)
Iyer, D., Vartak, S. V., Mishra, A., Goldsmith, G., Kumar, S., Srivastava, M., . . . Raghavan, S. C. (2016). Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain. The Federation of European Biochemical Societies (FEBS) Journal, 283(18), 3408-3437. doi:10.1111/febs.13815DOI: 10.1111/febs.13815
2015
Farahani, M., Rubbi, C., Liu, L., Slupsky, J. R., & Kalakonda, N. (2015). CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p. PLOS ONE, 10(10). doi:10.1371/journal.pone.0141429DOI: 10.1371/journal.pone.0141429
2014
CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide (Journal article)
Blocksidge, J., Glenn, M., Gandhi, A. K., Klippel, A., Pourdehnad, M., Chopra, R., & Kalakonda, N. (2014). CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide. BLOOD, 124(21). doi:10.1182/blood.V124.21.4682.4682DOI: 10.1182/blood.V124.21.4682.4682
Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia (Journal article)
Lin, K., Farahani, M., Yang, Y., Johnson, G. G., Oates, M., Atherton, M., . . . Pettitt, A. R. (2014). Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 167(3), 346-355. doi:10.1111/bjh.13043DOI: 10.1111/bjh.13043
Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy. (Journal article)
Duckworth, A., Glenn, M., Slupsky, J. R., Packham, G., & Kalakonda, N. (2014). Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy.. Blood, 123(21), 3277-3285. doi:10.1182/blood-2013-11-539049DOI: 10.1182/blood-2013-11-539049
CLL DERIVED EXOSOMES ENCAPSULATE SPECIFIC MICRORNAS AND INFLUENCE STROMAL CELL BEHAVIOUR (Conference Paper)
Farahani, M., Angelillo, P., Kelly, M., Liu, L., Rubbi, C., & Kalakonda, N. (2014). CLL DERIVED EXOSOMES ENCAPSULATE SPECIFIC MICRORNAS AND INFLUENCE STROMAL CELL BEHAVIOUR. In HAEMATOLOGICA Vol. 99 (pp. 40-41). Retrieved from https://www.webofscience.com/
COMPARISON OF GEMCITABINE VS. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA (Conference Paper)
Taylor, D., Angelillo, P., Ward, C., Collins, D., Salim, R., Pettitt, A., . . . Kalakonda, N. (2014). COMPARISON OF GEMCITABINE VS. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA. In HAEMATOLOGICA Vol. 99 (pp. 701). Retrieved from https://www.webofscience.com/
2013
Differential induction of PRDM1 in CLL cells is linked to the antigenic stimulus and stability of anergy (Journal article)
Duckworth, A., Glenn, M., Slupsky, J. R., Packham, G., & Kalakonda, N. (2013). Differential induction of PRDM1 in CLL cells is linked to the antigenic stimulus and stability of anergy.
High expression of TP53 mRNA is associated with allelic loss of 13q14 and short survival in chronic lymphocytic leukaemia (Conference Paper)
Lin, K., Johnson, G. G., Farahani, M., Oates, M., Atherton, M., Douglas, A., . . . Pettitt, A. R. (2013). High expression of TP53 mRNA is associated with allelic loss of 13q14 and short survival in chronic lymphocytic leukaemia. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 161 (pp. 43-44). Retrieved from https://www.webofscience.com/
MicroRNAs encapsulated by exosomes from CLL cells are critical for modulation of the tumour microenvironment (Journal article)
Farahani, M., Bee, A., Rubbi, C., & Kalakonda, N. (2013). MicroRNAs encapsulated by exosomes from CLL cells are critical for modulation of the tumour microenvironment.
Regulation and functional importance of Integrin expression in CLL cells (Journal article)
Glenn, M., Duckworth, A., Blocksidge, J., Till, K., Pettitt, A. R., Slupsky, J. R., & Kalakonda, N. (2013). Regulation and functional importance of Integrin expression in CLL cells.
SF3B1 mutational status impacts on LEDGF alternative splicing and disease behaviour in Chronic Lymphocytic Leukemia (Journal article)
Blocksidge, J., Glenn, M., Bee, A., Duckworth, A., Johnson, G., Pettitt, A. R., . . . Kalakonda, N. (2013). SF3B1 mutational status impacts on LEDGF alternative splicing and disease behaviour in Chronic Lymphocytic Leukemia.
The transcription factor Sp1 regulates PKCβ expression in chronic lymphocytic leukaemia cells (Journal article)
Al-Sanabra, O., Glenn, M., Kalakonda, N., & Slupsky, J. R. (2013). The transcription factor Sp1 regulates PKCβ expression in chronic lymphocytic leukaemia cells.
2012
DNA Methylation Abnormalities in Mature B-cell Lymphoid Neoplasms (Journal article)
Glenn, M., Duckworth, A., & Kalakonda, N. (2012). DNA Methylation Abnormalities in Mature B-cell Lymphoid Neoplasms. CML - Leukemia & Lymphoma, 20(4), 109-118.
DNA Methylation Abnormalities in Mature B-cell Lymphoid Neoplasms (Journal article)
Glenn, M., Duckworth, A., & Kalakonda, N. (2012). DNA Methylation Abnormalities in Mature B-cell Lymphoid Neoplasms. Unknown Journal, 4(20), 109-118.
2011
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p (Journal article)
Arumainathan, A., Kalakonda, N., & Pettitt, A. R. (2011). Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. EUROPEAN JOURNAL OF HAEMATOLOGY, 87(4), 372-375. doi:10.1111/j.1600-0609.2011.01667.xDOI: 10.1111/j.1600-0609.2011.01667.x
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. (Journal article)
Arumainathan, A., Kalakonda, N., & Pettitt, A. R. (2011). Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.. Eur J Haematol., 87(4), 372-375.
2008
Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1 (Journal article)
Kalakonda, N., Fischle, W., Boccuni, P., Gurvich, N., Hoya-Arias, R., Zhao, X., . . . Nimer, S. D. (2008). Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1. ONCOGENE, 27(31), 4293-4304. doi:10.1038/onc.2008.67DOI: 10.1038/onc.2008.67
2007
L3MBTL1, a histone-methylation-dependent chromatin lock (Journal article)
Trojer, P., Li, G., Sims, R. J. I. I. I., Vaquero, A., Kalakonda, N., Boccuni, P., . . . Reinberg, D. (2007). L3MBTL1, a histone-methylation-dependent chromatin lock. CELL, 129(5), 915-928. doi:10.1016/j.cell.2007.03.048DOI: 10.1016/j.cell.2007.03.048
2005
Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo (Journal article)
Zhou, P., Kalakonda, N., & Comenzo, R. L. (2005). Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. BRITISH JOURNAL OF HAEMATOLOGY, 128(5), 636-644. doi:10.1111/j.1365-2141.2005.05369.xDOI: 10.1111/j.1365-2141.2005.05369.x
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial (Journal article)
Gupta, S., Zhou, P., Hassoun, H., Kewalramani, T., Reich, L., Costello, S., . . . Comenzo, R. L. (2005). Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. BONE MARROW TRANSPLANTATION, 35(5), 441-447. doi:10.1038/sj.bmt.1704779DOI: 10.1038/sj.bmt.1704779
2004
Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells (Journal article)
MacGrogan, D., Kalakonda, N., Alvarez, S., Scandura, J. M., Boccuni, P., Johansson, B., & Nimer, S. D. (2004). Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells. GENES CHROMOSOMES & CANCER, 41(3), 203-213. doi:10.1002/gcc.20087DOI: 10.1002/gcc.20087
Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association (Journal article)
Cohen, A. D., Zhou, P., Xiao, Q., Fleisher, M., Kalakonda, N., Akhurst, T., . . . Comenzo, R. L. (2004). Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. BRITISH JOURNAL OF HAEMATOLOGY, 124(3), 309-314. doi:10.1046/j.1365-2141.2003.04779.xDOI: 10.1046/j.1365-2141.2003.04779.x
Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer (Journal article)
Stanziale, S. F., Stiles, B. M., Bhargava, A., Kerns, S. A., Kalakonda, N., & Fong, Y. M. (2004). Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. HUMAN GENE THERAPY, 15(6), 609-618. doi:10.1089/104303404323142051DOI: 10.1089/104303404323142051
2003
Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma (Journal article)
Hedvat, C. V., Comenzo, R. L., Teruya-Feldstein, J., Olshen, A. B., Ely, S. A., Osman, K., . . . Nimer, S. D. (2003). Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 122(5), 728-744. doi:10.1046/j.1365-2141.2003.04481.xDOI: 10.1046/j.1365-2141.2003.04481.x
Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination (Journal article)
Zhou, P., Zhang, Y., Martinez, C., Kalakonda, N., Nimer, S. D., & Comenzo, R. L. (2003). Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. BLOOD, 102(2), 477-479. doi:10.1182/blood-2002-12-3674DOI: 10.1182/blood-2002-12-3674
2002
Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. (Journal article)
Bezieau, S., Avet-Loiseau, H., Moisan, J. -P., & Bataille, R. (2002). Activating Ras mutations in patients with plasma-cell disorders: a reappraisal.. Blood, 100(3), 1101-1102. doi:10.1182/blood-2002-03-0795DOI: 10.1182/blood-2002-03-0795
2001
Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation (Journal article)
Kalakonda, N., Rothwell, D. G., Scarffe, J. H., & Norton, J. D. (2001). Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. BLOOD, 98(5), 1555-1560. doi:10.1182/blood.V98.5.1555DOI: 10.1182/blood.V98.5.1555
Timing of the appearance of multipotential and committed haemopoietic progenitors in peripheral blood after mobilization in patients with lymphoma (Journal article)
Hepburn, M. D., Nagesh, K., Heppleston, A. D., Cachia, P. G., & Pippard, M. J. (2001). Timing of the appearance of multipotential and committed haemopoietic progenitors in peripheral blood after mobilization in patients with lymphoma. CLINICAL AND LABORATORY HAEMATOLOGY, 23(2), 119-124. doi:10.1046/j.1365-2257.2001.00379.xDOI: 10.1046/j.1365-2257.2001.00379.x
2000
Tumour markers formonitoreng minimal residual disease in multiple myeloma (Journal article)
Rothwell, D. G., Kalakonda, N., Norton, J. D., Hawkins, R. E., & Chopra, R. (2000). Tumour markers formonitoreng minimal residual disease in multiple myeloma. Blood, 96(11 PART I).
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma (Journal article)
Robertson, J. D., Nagesh, K., Jowitt, S. N., Dougal, M., Anderson, H., Mutton, K., . . . Scarffe, J. H. (2000). Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. BRITISH JOURNAL OF CANCER, 82(7), 1261-1265. doi:10.1054/bjoc.1999.1088DOI: 10.1054/bjoc.1999.1088
1999
Content of long-term culture-initiating cells, clonogenic progenitors and CD34(+) cells in apheresis harvests of normal donors for allogeneic transplantation, and in patients with acute myeloid leukaemia or multiple myeloma (Journal article)
Kasper, C., Ryder, W. D. J., Durig, J., Nagesh, K., Scarffe, J. H., Beelen, D. W., . . . Testa, N. G. (1999). Content of long-term culture-initiating cells, clonogenic progenitors and CD34(+) cells in apheresis harvests of normal donors for allogeneic transplantation, and in patients with acute myeloid leukaemia or multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 104(2), 374-381. doi:10.1046/j.1365-2141.1999.01152.xDOI: 10.1046/j.1365-2141.1999.01152.x
1996
Current trials in acute leukaemia (Journal article)
Nagesh, K., Jowitt, S. N., & Scarffe, J. H. (1996). Current trials in acute leukaemia. BRITISH JOURNAL OF HOSPITAL MEDICINE, 56(10), 532-536. Retrieved from https://www.webofscience.com/
Recurrent septicaemia in a neutropenic patient with typhlitis (Journal article)
Sadullah, S., Nagesh, K., Johnston, D., McCullough, J. B., Murray, F., & Cachia, P. G. (1996). Recurrent septicaemia in a neutropenic patient with typhlitis. CLINICAL AND LABORATORY HAEMATOLOGY, 18(3), 215-217. doi:10.1046/j.1365-2257.1996.00160.xDOI: 10.1046/j.1365-2257.1996.00160.x
